Lerisetron Explained

Lerisetron (code name F-0930-RS) is a drug which acts as an antagonist at the 5-HT₃ receptor.^[1] It is a potent antiemetic^{[2] [3]} and was in clinical trials for the treatment of nausea associated with cancer chemotherapy.^[4]

See also

• 5-HT₃ antagonist

Notes and References

1. Orjales A, Mosquera R, Labeaga L, Rodes R . New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation . Journal of Medicinal Chemistry . 40 . 4 . 586–93 . February 1997 . 9046349 . 10.1021/jm960442e .
2. Gomez-de-Segura IA, Grande AG, De Miguel E . Antiemetic effects of Lerisetron in radiation-induced emesis in the dog . Acta Oncologica . 37 . 7–8 . 759–63 . 1998 . 10050999 . 10.1080/028418698430160 .
3. Cooper M, Sologuren A, Valiente R, Smith J . Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers . Arzneimittel-Forschung . 52 . 9 . 689–94 . 2002 . 12404884 . 10.1055/s-0031-1299952 . 24423582 .
4. Huckle R . Lerisetron. FAES . Current Opinion in Investigational Drugs . 4 . 7 . 874–7 . July 2003 . 14619411 .